Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study

MD Open. 2024 Sep 20;10:e004318 doi: 10.1136/rmdopen-2024-004318

Kristensen et al. compared 14 PsA drugs across five treatment classes, evaluating their real-world effectiveness over three months. Ixekizumab showed rapid effectiveness on joint disease activity and skin outcomes, performing better than IL-12/23i and IL-23i, and comparable to TNFi and JAKi. More patients with active psoriasis achieved minimal disease activity with Ixekizumab than other therapies.

The study aimed to assess early treatment responses in PsA patients across six countries, using IL-17Ai, TNFi, and JAKi. The research highlights the superior performance of IXE in skin-related outcomes within a diverse, real-world patient population.

Keywords:


Publication thumbnail: Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study
LinkedIn